NO20011025L - Selektiv behandling av endoteliale somatostatinreseptorer - Google Patents

Selektiv behandling av endoteliale somatostatinreseptorer

Info

Publication number
NO20011025L
NO20011025L NO20011025A NO20011025A NO20011025L NO 20011025 L NO20011025 L NO 20011025L NO 20011025 A NO20011025 A NO 20011025A NO 20011025 A NO20011025 A NO 20011025A NO 20011025 L NO20011025 L NO 20011025L
Authority
NO
Norway
Prior art keywords
selective treatment
somatostatin receptors
endothelial
endothelial somatostatin
receptors
Prior art date
Application number
NO20011025A
Other languages
English (en)
Other versions
NO20011025D0 (no
Inventor
York Hsiang
Alison Buchan
Julia G Levy
Phillippe Maria Clota Margaron
Original Assignee
Univ British Columbia
Quadra Logic Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia, Quadra Logic Tech Inc filed Critical Univ British Columbia
Publication of NO20011025D0 publication Critical patent/NO20011025D0/no
Publication of NO20011025L publication Critical patent/NO20011025L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20011025A 1998-09-01 2001-02-28 Selektiv behandling av endoteliale somatostatinreseptorer NO20011025L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002246791A CA2246791A1 (en) 1998-09-01 1998-09-01 Treatment of endothelium with somatostatin analogues
PCT/CA1999/000800 WO2000012111A2 (en) 1998-09-01 1999-09-01 Selective treatment of endothelial somatostatin receptors

Publications (2)

Publication Number Publication Date
NO20011025D0 NO20011025D0 (no) 2001-02-28
NO20011025L true NO20011025L (no) 2001-03-30

Family

ID=4162807

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20011025A NO20011025L (no) 1998-09-01 2001-02-28 Selektiv behandling av endoteliale somatostatinreseptorer

Country Status (10)

Country Link
US (2) US20020137676A1 (no)
EP (1) EP1107780A2 (no)
JP (1) JP2002523465A (no)
CN (1) CN1320042A (no)
AU (1) AU769289B2 (no)
CA (1) CA2246791A1 (no)
MX (1) MXPA01002240A (no)
NO (1) NO20011025L (no)
NZ (1) NZ510543A (no)
WO (1) WO2000012111A2 (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1040837A3 (en) * 1999-02-26 2002-01-02 Erasmus Universiteit Rotterdam Medicaments for the treatment of a choroidal neovascularization (CNV) related disorder
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
AU2002243552C1 (en) * 2001-01-12 2006-08-31 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
EP1399179A4 (en) * 2001-06-25 2009-07-01 Ipsen Pharma PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROLIFERATION OF HYPOPHYENADENOMES AND METHOD FOR THEIRIR USE
US20030207811A1 (en) * 2002-05-03 2003-11-06 Schrier Bruce K. Method of treating retinopathy of prematurity using somatostatin analogs
EP1367397A1 (en) * 2002-05-29 2003-12-03 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with somatostatin receptor 1 (SSTR1)
EP1369697A1 (en) * 2002-06-07 2003-12-10 Bayer Ag Diagnostics and therapeutics for diseases associated with somatostatin receptor 4 (SSTR4)
AU2003259172A1 (en) * 2002-07-24 2004-02-09 The Salk Institute For Biological Studies Receptor (sstr4)- selective somatostatin analogs
EP1566184A4 (en) * 2002-10-31 2006-07-05 Senju Pharma Co REMEDY FOR THE TREATMENT OF CORNEAL DISEASE
AU2004273986B2 (en) * 2003-09-15 2010-04-22 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use in angiogenesis
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
WO2005041901A2 (en) * 2003-11-03 2005-05-12 Elixir Pharmaceuticals, Inc. Therapeutics using somatostatin agonists
WO2005082845A1 (en) * 2004-02-27 2005-09-09 Oy Juvantia Pharma Ltd Novel therapies with somatostatin receptor agonists
WO2005082844A1 (en) * 2004-02-27 2005-09-09 Oy Juvantia Pharma Ltd Treatment of diseases by using a somatostatin receptor agonist
GB0425258D0 (en) * 2004-11-16 2004-12-15 Novartis Ag Organic compounds
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
WO2007035612A2 (en) 2005-09-16 2007-03-29 Ordway Research Institute, Inc. Polyphenol conjugates as rgd-binding compounds and methods of use
US8226949B2 (en) * 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
PL2076535T3 (pl) 2006-10-16 2013-08-30 Salk Inst Biological Studies Antagoniści somatostatyny selektywni względem receptora (SSTR2)
US8691761B2 (en) 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
EP2120913B1 (en) * 2006-12-22 2015-01-21 NanoPharmaceuticals LLC Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US20100159021A1 (en) * 2008-12-23 2010-06-24 Paul Davis Small Molecule Ligands of the Integrin RGD Recognition Site and Methods of Use
WO2010120506A1 (en) * 2009-03-31 2010-10-21 Ordway Research Institute, Inc. Combination treatment of cancer with cetuximab and tetrac
WO2010148007A2 (en) 2009-06-17 2010-12-23 Ordway Research Institute, Inc. Nanoparticle and polymer formulations for thyroid hormone, analogs, antagonists, and formulations and uses thereof
WO2011151782A1 (en) 2010-06-02 2011-12-08 Preglem Sa A role for somatostatin to modulate initiation of follicular growth in the human ovary
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
EP3463477A4 (en) 2016-06-07 2020-03-04 NanoPharmaceuticals LLC NON-CLeavable POLYMER CONJUGATED WITH THYROID ANTAGONISTS OF avß3 INTEGRIN
CA3053806A1 (en) 2017-03-09 2018-09-13 Corcept Therapeutics, Inc. Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
JP7099717B2 (ja) * 2019-09-30 2022-07-12 株式会社理研バイオ ソマトスタチン受容体
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485101A (en) * 1983-10-11 1984-11-27 Administrators Of The Tulane Educational Fund Peptides
US4904642A (en) * 1985-09-12 1990-02-27 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
IT1203515B (it) * 1987-02-26 1989-02-15 Indena Spa Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
US5174859A (en) * 1990-04-11 1992-12-29 Hpd Incorporated Method for treating mechanical pulp plant effluent
US5409894A (en) * 1991-03-14 1995-04-25 Sandoz Ltd. Method of preventing balloon catheterization blood vessel damage
US6001960A (en) * 1992-09-01 1999-12-14 The Trustees Of The University Of Pennsylvania Synthetic somatostatin mimics
US5597894A (en) * 1995-06-05 1997-01-28 The Louisiana State University Medical Center Foundation Multi-tyrosinated somatostatin analogs
TW357143B (en) * 1995-07-07 1999-05-01 Novartis Ag Benzo[g]quinoline derivatives
US5750499A (en) * 1995-10-18 1998-05-12 The Salk Institute For Biological Studies Receptor-selective somatostatin analogs
ZA974147B (en) * 1996-05-14 1997-11-14 Novo Nordisk As Somatostatin agonists and antagonists.
DK1019050T3 (da) * 1997-06-24 2002-07-08 Novo Nordisk As Anvendelse af somatostatinagonister og -antagonister til behandling af sygdomme i forbindelse med øjet
US6124256A (en) * 1998-03-27 2000-09-26 Haeyry; Pekka Method for the prevention of a patient's fibroproliferative vasculopathy

Also Published As

Publication number Publication date
CA2246791A1 (en) 2000-03-01
CN1320042A (zh) 2001-10-31
WO2000012111A2 (en) 2000-03-09
MXPA01002240A (es) 2003-08-20
AU769289B2 (en) 2004-01-22
JP2002523465A (ja) 2002-07-30
WO2000012111A3 (en) 2000-05-25
NZ510543A (en) 2004-01-30
US20060089299A1 (en) 2006-04-27
US20020137676A1 (en) 2002-09-26
EP1107780A2 (en) 2001-06-20
AU5499799A (en) 2000-03-21
NO20011025D0 (no) 2001-02-28

Similar Documents

Publication Publication Date Title
NO20011025L (no) Selektiv behandling av endoteliale somatostatinreseptorer
DE69908713D1 (de) Selektive Helligkeitserweiterung
CY2012029I1 (el) Νεα μορφη της s-ομεπραζολης
DE60026169D1 (de) Selektive neurokinin-antagonisten
DK0951447T3 (da) Vandbehandling
IS5581A (is) Ný efnasambönd og notkun þeirra sem jákvæðir beinar AMPA-viðtaka
NO20013665L (no) Kaliumsalt av (S)-omeprazol
ID24458A (id) Modifikasi rheologi in-sito poliolefin
PT1100326E (pt) Microcapsulas de libertacao activada por bases
PT1036072E (pt) Antagonistas de receptores de trombina
PT869121E (pt) Derivados de propanolamina hipolipidemicos
DE60023454D1 (de) Lagenmaterialen mit tensid-modifizierten chelatbildern behandelt
ID28032A (id) TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2
DE60026821D1 (de) Behandlung von bohrspülung
PT1178984E (pt) Derivados de 1-trifluorometil-4-hidroxi-7-piperidinilamimometilcromano
NO20014845D0 (no) Anvendelse av arylalkanoylpyridaziner
FI980519A0 (fi) Foerfarande foer behandling av massa
PT1232141E (pt) Eteres de o-desmetil-venlafaxina
DE29903644U1 (de) Balkonbrüstung
SE9803428D0 (sv) Blocking of alfa2beta1-receptors
UA2926S (uk) Парапет
DE29823228U1 (de) Spezialpflaster
FI980433A0 (fi) Foerfarande foer utnyttjande i samband med tillslutandet av en vaetskefoerpackning
SE9803550D0 (sv) Method of application
SE9802223D0 (sv) Method of application

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application